Spotlight
Specialty
Partners
CME/CE
Data Updates on Immunotherapy Combinations in Multiple Myeloma
Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.
EP: 1.Data Updates in the Frontline Treatment of Patients With Transplant-Eligible Multiple Myeloma
EP: 2.Considerations for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
EP: 3.Defining Frailty in Multiple Myeloma for Optimal Treatment
EP: 4.Approaches to Treatment Duration in Newly-Diagnosed Multiple Myeloma
EP: 5.Relapse in Multiple Myeloma: Biochemical and Chemical
EP: 6.Data Updates in the Treatment of Relapsed Multiple Myeloma
EP: 7.Strategies for Treatment of Multiple Myeloma at Late Relapse
EP: 8.Quadruplet Combination Therapies in Relapsed Multiple Myeloma
EP: 9.Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma
EP: 10.CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection
EP: 11.BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma
EP: 12.Retreatment with a BCMA-Targeting Bispecific for R/R MM
Now Viewing
EP: 13.Data Updates on Immunotherapy Combinations in Multiple Myeloma
EP: 14.Targets in Multiple Myeloma: GPRC5D
EP: 15.Targets in Multiple Myeloma: FcRH5
EP: 16.Managing Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Multiple Myeloma
EP: 17.Preventing Infection in Patients with Multiple Myeloma During Treatment
EP: 18.Does Belantamab Have a Place in Multiple Myeloma Treatment?
EP: 19.Unmet Needs and Future Perspectives in Multiple Myeloma Care
Related Videos
Related Content
%20copy.png?fit=crop&auto=format)
